- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04983225
The Safety and Tolerability of Initial Periodontal Therapy Combined With Human Dental Pulp Stem Cell Injection in the Treatment of Chronic Periodontitis
A Randomized, Double-blind, Blank Controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Tolerability of Initial Periodontal Therapy Combined With Human Dental Pulp Stem Cell Injection in the Treatment of Chronic Periodontitis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Beijng
-
Beijing, Beijng, China, 100191
- Peking University Third Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18 to 65 years old (including threshold ), unlimited gender.
- Radiological examination of the periodontal defect site shows vertical bone defect, and the probing depth (PD) is 4 to 8 mm.
- Voluntarily participate in the clinical study, understand and sign the informed consent, and comply with the relevant regulations during the study period and within 18 months after the end of the study.
Exclusion Criteria:
- Subjects with severe periodontal diseases (alveolar bone resorption generally exceeds two-thirds of the tooth root length) and affects the study tooth judgment;
- The grade of studied tooth looseness ≥ grade 2 (only buccolingual movement is defined as grade 1; buccolingual and mesiodistal movement is grade 2; vertical loosening is grade 3);
- Subjects with surgical treatment of previous periodontal bone defect sites and adjacent periodontal tissues;
- Subjects with non-steroid anti-inflammatory drug, steroid hormone therapy, and/or hormone (except topical hormones) treatment, bisphosphonates within the previous 3 months before screening;
- Subjects with severe systemic infection within the previous 3 months before screening; or antibiotics treatment within 72 h before screening;
- Subjects with uncontrolled hypertension within 1 month before screening (defined as sitting systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 95 mmHg after receiving the optimal antihypertensive therapy);
- Subjects with systemic diseases (including but not limited to: malignant tumor or with positive tumor examination during screening, diabetes, heart failure caused by heart disease, myocardial infarction within the first 6 months before screening, angina symptoms within the first 6 months before screening, and congenital heart disease, etc.);
- Subjects who are known to be allergic to any of the materials used in the treatment;
- Subjects with the allergic constitution and previous history of allergy to blood products;
- Laboratory test (any of them meets): abnormal liver function: ALT > 80 U/L or AST > 70 U/L; abnormal renal function: serum creatinine (picric acid method) > 97 μmol/L;
- Subjects with a bleeding tendency or coagulant dysfunction (INR ≥ 1.5 × ULN, or APTT ≥ 1.5 × ULN (except the ones who are receiving anticoagulant therapy)) or serious hematologic diseases (such as grade 3 or above anemia (Hb < 80 g/L); grade 2 or above thrombocytopenia ( < 75.0 × 109 /L))
- Viral serology positive (HBsAg, HCV antibody, HIV antibody, treponema pallidum antibody) positive;
- Subjects with unprotected sex within the previous 1 month before the screening;
- Pregnant or lactating women, or subjects with a positive result of β-HCG before the screening, or subjects who are unable or unwilling to take contraceptive measures under the investigator instruction;
- Women with oral contraceptives;
- Subjects with a history of smoking addiction in the previous 12 months before the screening (the number of cigarettes smoked per day ≥ 10);
- Subjects with mental or conscious disorders;
- Subjects who participated in other clinical studies within 3 months before the screening;
- Other circumstances deemed inappropriate by the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1×10^6 cells/site group
Human Dental Pulp Stem Cells Injection: 1×10^6 cells/periodontal defect site.
|
Investigational drugs: based on initial periodontal therapy (supragingival cleansing, subgingival scaling and root planning), human dental pulp stem cell injection will be given for a single local injection;
Other Names:
|
Experimental: 5×10^6 cells/site group
Human Dental Pulp Stem Cells Injection: 5×10^6 cells/periodontal defect site.
|
Investigational drugs: based on initial periodontal therapy (supragingival cleansing, subgingival scaling and root planning), human dental pulp stem cell injection will be given for a single local injection;
Other Names:
|
Experimental: 1×10^7 cells/site group
Human Dental Pulp Stem Cells Injection: 1×10^7 cells/periodontal defect site.
|
Investigational drugs: based on initial periodontal therapy (supragingival cleansing, subgingival scaling and root planning), human dental pulp stem cell injection will be given for a single local injection;
Other Names:
|
Experimental: 2×10^7 cells/two sites group
Human Dental Pulp Stem Cells Injection: 1×10^7 cells/periodontal defect site, two locations in total, and the total cell injection volume is 2 × 10^7 cells/2 periodontal defect sites.
|
Investigational drugs: based on initial periodontal therapy (supragingival cleansing, subgingival scaling and root planning), human dental pulp stem cell injection will be given for a single local injection;
Other Names:
|
Experimental: 3~4×10^7 cells/three or four sites group
Human Dental Pulp Stem Cells Injection: 1×10^7 cells/periodontal defect site, three or four locations in total, and the total cell injection volume is 3 × 10^7 to 4 × 10^7 cells/3 to 4 periodontal defect sites.
|
Investigational drugs: based on initial periodontal therapy (supragingival cleansing, subgingival scaling and root planning), human dental pulp stem cell injection will be given for a single local injection;
Other Names:
|
Placebo Comparator: Saline solution group
Saline solution: 0.6mL/periodontal defect site.
|
Blank control: initial Basal periodontal therapy (supragingival cleansing, subgingival scaling and root planning) followed by a single local injection of normal saline.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes from baseline in respiration rate of Vital Signs.
Time Frame: within 180 days after administration.
|
Respiration rate in mg(μl)/(h·g)
|
within 180 days after administration.
|
Changes from baseline in heart rate of Vital Signs.
Time Frame: within 180 days after administration.
|
Heart rate in beats per minute
|
within 180 days after administration.
|
Changes from baseline in blood pressure of Vital Signs.
Time Frame: within 180 days after administration.
|
Blood pressure in mmHg
|
within 180 days after administration.
|
Changes from baseline in body temperature of Vital Signs.
Time Frame: within 180 days after administration.
|
Body temperature in Celsius degree
|
within 180 days after administration.
|
Changes from baseline in red blood cell count of Laboratory Examination
Time Frame: within 180 days after administration.
|
Red blood cell count in whole blood is reported in the form of number.
|
within 180 days after administration.
|
Changes from baseline in white blood cell count of Laboratory Examination
Time Frame: within 180 days after administration.
|
White blood cell count in whole blood is reported in the form of number.
|
within 180 days after administration.
|
Changes from baseline in neutrophil count of Laboratory Examination
Time Frame: within 180 days after administration.
|
Neutrophil count in whole blood is reported in the form of number.
|
within 180 days after administration.
|
Changes from baseline in lymphocyte count of Laboratory Examination
Time Frame: within 180 days after administration.
|
Lymphocyte count in whole blood is reported in the form of number.
|
within 180 days after administration.
|
Changes from baseline in platelet count of Laboratory Examination
Time Frame: within 180 days after administration.
|
Platelet count in whole blood is reported in the form of number.
|
within 180 days after administration.
|
Changes from baseline in hemoglobin of Laboratory Examination
Time Frame: within 180 days after administration.
|
Changes of hemoglobin concentration(g/dL)in whole blood will be recorded.
|
within 180 days after administration.
|
Changes from baseline in PT of Laboratory Examination
Time Frame: within 180 days after administration.
|
Prothrombin time (PT) is a screening test for exogenous coagulation factors.
|
within 180 days after administration.
|
Changes from baseline in INR of Laboratory Examination
Time Frame: within 180 days after administration.
|
International standardized ratio (INR) is calculated from prothrombin time and international sensitivity index (ISI) of the reagent.
|
within 180 days after administration.
|
Changes from baseline in APTT of Laboratory Examination
Time Frame: within 180 days after administration.
|
Activated partial thromboplastin time (APTT) is a screening test for endogenous coagulation factors.
|
within 180 days after administration.
|
Changes from baseline in total bilirubin of Laboratory Examination
Time Frame: within 180 days after administration.
|
Changes of total bilirubin concentration (μmol/L) in serum will be recorded.
|
within 180 days after administration.
|
Changes from baseline in direct bilirubin of Laboratory Examination
Time Frame: within 180 days after administration.
|
Changes of direct bilirubin concentration (μmol/L) in serum will be recorded.
|
within 180 days after administration.
|
Changes from baseline in ALT of Laboratory Examination
Time Frame: within 180 days after administration.
|
Changes of ALT concentration (U/L) in serum will be recorded.
|
within 180 days after administration.
|
Changes from baseline in AST of Laboratory Examination
Time Frame: within 180 days after administration.
|
Changes of AST concentration (U/L) in serum will be recorded.
|
within 180 days after administration.
|
Changes from baseline in total protein of Laboratory Examination
Time Frame: within 180 days after administration.
|
Changes of total protein concentration (g/L) in serum will be recorded.
|
within 180 days after administration.
|
Changes from baseline in albumin of Laboratory Examination
Time Frame: within 180 days after administration.
|
Changes of albumin concentration (g/L) in serum will be recorded.
|
within 180 days after administration.
|
Changes from baseline in total bile acid of Laboratory Examination
Time Frame: within 180 days after administration.
|
Changes of total bile acid concentration (μmol/L) in serum will be recorded.
|
within 180 days after administration.
|
Changes from baseline in urea of Laboratory Examination
Time Frame: within 180 days after administration.
|
Changes of urea concentration (mmol/L) in serum will be recorded.
|
within 180 days after administration.
|
Changes from baseline in creatinine of Laboratory Examination
Time Frame: within 180 days after administration.
|
Changes of creatinine concentration (μmol/L) in serum will be recorded.
|
within 180 days after administration.
|
Changes from baseline in uric acid of Laboratory Examination
Time Frame: within 180 days after administration.
|
Changes of uric acid concentration (μmol/L) in serum will be recorded.
|
within 180 days after administration.
|
Changes from baseline in glucose of Laboratory Examination
Time Frame: within 180 days after administration.
|
Changes of glucose concentration (mmol/L) in serum will be recorded.
|
within 180 days after administration.
|
Changes from baseline in potassium of Laboratory Examination
Time Frame: within 180 days after administration.
|
Changes of potassium concentration (mmol/L) in serum will be recorded.
|
within 180 days after administration.
|
Changes from baseline in sodium of Laboratory Examination
Time Frame: within 180 days after administration.
|
Changes of sodium concentration (mmol/L) in serum will be recorded.
|
within 180 days after administration.
|
Changes from baseline in chlorine of Laboratory Examination
Time Frame: within 180 days after administration.
|
Changes of chlorine concentration (mmol/L) in serum will be recorded.
|
within 180 days after administration.
|
Changes from baseline in CPR of Laboratory Examination
Time Frame: within 180 days after administration.
|
C-reactive protein (CPR) is a phylogenetically highly conserved plasma protein, changes of its plasma concentration(mg/L)will be recorded.
|
within 180 days after administration.
|
Changes from baseline in Detection of infectious diseases of Laboratory Examination
Time Frame: within 180 days after administration.
|
It refers to infectious diseases screening.
|
within 180 days after administration.
|
Changes from baseline in IgA of Laboratory Examination
Time Frame: within 180 days after administration.
|
Changes of IgA concentration (g/L)in serum will be recorded.
|
within 180 days after administration.
|
Changes from baseline in IgG of Laboratory Examination
Time Frame: within 180 days after administration.
|
Changes of IgG concentration (g/L)in serum will be recorded.
|
within 180 days after administration.
|
Changes from baseline in IgM of Laboratory Examination
Time Frame: within 180 days after administration.
|
Changes of IgM concentration (g/L)in serum will be recorded.
|
within 180 days after administration.
|
Changes from baseline in total IgE of Laboratory Examination
Time Frame: within 180 days after administration.
|
Changes of total IgE concentration (g/L)in serum will be recorded.
|
within 180 days after administration.
|
Changes from baseline in Pregnancy test of Laboratory Examination
Time Frame: within 180 days after administration.
|
Pregnancy test will be tested in female subjects
|
within 180 days after administration.
|
Changes from baseline in urine specific gravity of Laboratory Examination
Time Frame: within 180 days after administration.
|
Changes of urine specific gravity will be recorded.
|
within 180 days after administration.
|
Changes from baseline in urine pH of Laboratory Examination
Time Frame: within 180 days after administration.
|
Changes of urine pH value will be recorded.
|
within 180 days after administration.
|
Changes from baseline in urine glucose of Laboratory Examination
Time Frame: within 180 days after administration.
|
Changes of urine glucose will be examined by qualitative test (positive or negative).
|
within 180 days after administration.
|
Changes from baseline in urine protein of Laboratory Examination
Time Frame: within 180 days after administration.
|
Changes of urine protein will be examined by qualitative test (positive or negative).
|
within 180 days after administration.
|
Changes from baseline in urine ketone body of Laboratory Examination
Time Frame: within 180 days after administration.
|
Changes of urine ketone body will be examined by qualitative test (positive or negative).
|
within 180 days after administration.
|
Changes from baseline in urine white blood cell of Laboratory Examination
Time Frame: within 180 days after administration.
|
Changes of white blood cell in urine will be examined by qualitative test (positive or negative).
|
within 180 days after administration.
|
Changes from baseline in urine bilirubin of Laboratory Examination
Time Frame: within 180 days after administration.
|
Changes of urine bilirubin will be examined by qualitative test (positive or negative).
|
within 180 days after administration.
|
Changes from baseline in urine occult blood of Laboratory Examination
Time Frame: within 180 days after administration.
|
Changes of urine occult blood will be examined by qualitative test (positive or negative).
|
within 180 days after administration.
|
Changes from baseline in stool form of Laboratory Examination
Time Frame: within 180 days after administration.
|
Stool form is classified by Bristol Stool Form Scale into 7 categories scored from 1 to 7; (1) Separate hard lumps like nuts (difficult to pass); (2) Sausage-shaped but lumpy; (3) Like a sausage but with cracks on its surface; (4) Like a sausage or snake, smooth and soft; (5) Soft blobs with clear-cut edges (passed easily); (6) Fluffy pieces with ragged edges, a mushy stool; (7) Watery, no solid pieces, entirely liquid.
|
within 180 days after administration.
|
Changes from baseline in stool white blood cells of Laboratory Examination
Time Frame: within 180 days after administration.
|
White blood cell count in stools is reported in the form of number.
|
within 180 days after administration.
|
Changes from baseline in stool red blood cells of Laboratory Examination
Time Frame: within 180 days after administration.
|
Red blood cell count in stools is reported in the form of number.
|
within 180 days after administration.
|
Changes from baseline in stool parasite egg of Laboratory Examination
Time Frame: within 180 days after administration.
|
Parasite egg count in stools is reported in the form of number.
|
within 180 days after administration.
|
Changes from baseline in stool OBT of Laboratory Examination
Time Frame: within 180 days after administration.
|
Changes of stool OBT will be examined by qualitative test (positive or negative).
|
within 180 days after administration.
|
Changes from baseline in ECG
Time Frame: within 180 days after administration.
|
The cardiac rhythm is showed in ECG in the form of continuous curve.
Changes of this continuous curve will be recorded.
|
within 180 days after administration.
|
Incidence of Treatment-Emergent Adverse Event
Time Frame: within 180 days after administration.
|
Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events during the study period, and the severity of adverse events is determined according to the NCI CTCAE version 5.0.
|
within 180 days after administration.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Event
Time Frame: within 360 days and 720 days after administration
|
Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events within 360 days and 720 days after administration, and the severity of adverse events is determined according to the NCI CTCAE version 5.0.
|
within 360 days and 720 days after administration
|
Change from baseline in Clinical Attachment Level (AL).
Time Frame: at baseline, 90 days, 180 days ,360 days, 720 days.
|
Clinical Attachment Level (AL) may be assessed to the nearest millimeter by means of a graduated probe and expressed as the distance in millimeters from the CEJ to the bottom of the probeable gingival/periodontal pocket. The clinical assessment requires the measurement of the distance from the free gingival margin (FGM) to the CEJ for each tooth surface. After this recording, AL may be calculated from the periodontal chart (i.e. PPD - distance CEJ to FGM). In cases with gingival recession, the distance FGM-CEJ turns negative and, hence, will be added to the PPD to determine AL. |
at baseline, 90 days, 180 days ,360 days, 720 days.
|
Change from baseline in Probing Depth (PD).
Time Frame: at baseline, 90 days, 180 days ,360 days, 720 days.
|
The probing depth is the distance from the gingival margin to the bottom of the gingival sulcus/pocket, is measured to the nearest millimeter by means of periodontal probe.
|
at baseline, 90 days, 180 days ,360 days, 720 days.
|
Change from baseline in Probing Bleeding Index (BI)
Time Frame: at baseline, 90 days, 180 days ,360 days, 720 days.
|
A periodontal probe is inserted to the "bottom" of the gingival/periodontal pocket applying light force and is moved gently along the tooth (root) surface.
If bleeding is provoked by this examination, the site examined is considered bleeding on probing-positive and, hence, inflamed.
Probing Bleeding Index is divided into 5 grades: 0, 1, 2, 3 and 4.
|
at baseline, 90 days, 180 days ,360 days, 720 days.
|
Change from baseline in Gingival recession (GR)
Time Frame: at baseline, 90 days, 180 days ,360 days, 720 days.
|
Exposure of the tooth through apical migration of the gingiva is called gingival recession.
Recorded as the distance in millimeters from the CEJ to the gingival margin.
|
at baseline, 90 days, 180 days ,360 days, 720 days.
|
Change from baseline in Tooth Mobility (TM).
Time Frame: at baseline, 90 days, 180 days ,360 days, 720 days.
|
The continuous loss of the supporting tissues during periodontal disease progression may result in increased tooth mobility, which is divided into 3 degree: I°, II°, and III°.
Changes from baseline in tooth mobility will be recorded.
|
at baseline, 90 days, 180 days ,360 days, 720 days.
|
Changes from baseline in height of the periodontal bone defect and average density of alveolar ridge.
Time Frame: at baseline, 90 days, 180 days ,360 days, 720 days.
|
Changes in the height of the periodontal bone defect and the mean alveolar ridge density will be detected by Cone Beam Computed Tomography (CBCT)
|
at baseline, 90 days, 180 days ,360 days, 720 days.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Xiao Wang, Master, Department of Stomatology, Peking University Third Hospital, Beijing, China.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SH-hDP-MSC-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Periodontitis
-
Azienda Socio Sanitaria Territoriale degli Spedali...Università degli Studi di FerraraCompletedPeriodontitis, Aggressive | Periodontitis, AdultItaly
-
Panineeya Mahavidyalaya Institute of Dental Sciences...Research Institute for Genetic and Human TherapyUnknownGeneralized Adult Periodontitis
-
Asem Mohammed Kamel AliCompletedMolar-incisor Pattern Grade C Periodontitis ( Localized Aggressive Periodontitis) | Generalized Grade C Periodontitis (Generalized Aggressive Periodontitis)Egypt
-
Columbia UniversityCompletedPeriodontal Diseases | Generalized Moderate Chronic Periodontitis | Generalized Severe Chronic PeriodontitisUnited States
-
Postgraduate Institute of Dental Sciences RohtakUnknownChronic Apical PeriodontitisIndia
-
University of SienaNot yet recruitingPeriodontitis, AdultItaly
-
Lithuanian University of Health SciencesCompleted
-
Louisiana State University Health Sciences Center...CompletedPeriodontitis, AdultUnited States
-
University of BergenCompletedPeriodontitis | Adult Periodontitis
-
Cairo UniversityUnknownPeriodontitis, AdultEgypt
Clinical Trials on Human Dental Pulp Stem Cells
-
CAR-T (Shanghai) Biotechnology Co., Ltd.Unknown
-
Renmin Hospital of Wuhan UniversityBeijing SH Bio-Tech Corporation, Beijing (CN); Utooth Biological Technology...Recruiting
-
Peking University Third HospitalCapital Medical UniversityRecruiting
-
Baskent UniversityCompletedPeriodontal Pocket | Third Molar | Stem CellTurkey
-
Azienda Ospedaliera Santa Maria, Terni, ItalyAzienda Ospedaliero Universitaria Maggiore della Carita; Università di Padova...CompletedAmyotrophic Lateral SclerosisItaly
-
StemCells, Inc.WithdrawnNeuronal Ceroid LipofuscinosisUnited States
-
IRCCS San RaffaeleFondazione Italiana Sclerosi MultiplaCompletedProgressive Multiple SclerosisItaly
-
Joshua M HareNational Heart, Lung, and Blood Institute (NHLBI)CompletedDiabetes Mellitus, Type 2United States
-
Joseph C. WuCalifornia Institute for Regenerative Medicine (CIRM)RecruitingChronic Ischemic Left Ventricular DysfunctionUnited States
-
Shenzhen Beike Bio-Technology Co., Ltd.The Second Affiliated Hospital of Kunming Medical UniversityUnknown